Core Viewpoint - Heng Rui Medicine announced the approval of clinical trial notifications for four injectable drugs by the National Medical Products Administration, indicating a significant advancement in its oncology pipeline [1] Group 1: Clinical Trial Approvals - The company’s subsidiaries received approval for SHR-7787, SHR-4849, Bevacizumab, and Atezolizumab for clinical trials [1] - SHR-7787 is a first-class therapeutic biological product that activates T cells to target and kill tumor cells [1] - SHR-4849 is an antibody-drug conjugate targeting DLL3, designed to treat advanced malignant solid tumors by specifically binding to DLL3 antigens on tumor cells [1] Group 2: Drug Mechanisms - Bevacizumab is a humanized anti-VEGF monoclonal antibody, commonly used in cancer treatment [1] - Atezolizumab is a humanized anti-PD-L1 monoclonal antibody that blocks the PD-1/PD-L1 pathway, reactivating the immune system's anti-tumor activity [1]